Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading

Bone

Volumn 46, Issue 1, 2010, Pages 203-207

  Feher, Anthony ^a   Koivunemi, Andrew ^a   Koivunemi, Mark ^a   Fuchs, Robyn K ^a,b   Burr, David B ^a,b   Phipps, Roger J ^c   Reinwald, Susan ^a   Allen, Matthew R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Alendronate; Ovariectomy; Risedronate; Ulna loading; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; CONTROLLED STUDY; DIAPHYSIS; DRUG EFFECT; ESTROGEN DEFICIENCY; FEMALE; IN VIVO STUDY; LOAD CARRYING CAPACITY; MECHANICAL STIMULATION; NONHUMAN; OSSIFICATION; OVARIECTOMY; PERIOSTEUM; RAT; SINGLE DRUG DOSE; ULNA; WEIGHT BEARING;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; IMIDAZOLES; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; RATS;

EID: 72049103657     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.023     Document Type: Article

References (49)

1. Alhlborg H., Johnell O., Turner C., Rannevik G., and Karlsson M. Bone loss and bone size after menopause. N. Engl. J. Med. 349 (2003) 327-334
2. Cooper C., and Melton L. Epidemiology of osteoporosis. Trends Endocrinol. Metab. 3 (1992) 224-229
3. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 359 (2002) 1841-1850
4. Turner R.T., Riggs B.L., and Spelsberg T.C. Skeletal effects of estrogen. Endocr. Rev. 15 (1994) 275-300
5. Turner R.T., Hannon K.S., Demers L.M., Buchanan J., and Bell N.H. Differential effects of gonadal function on bone histomorphometry in male and female rats. J. Bone Miner. Res. 4 (1989) 557-563
6. Wakley G.K., Evans G.L., and Turner R.T. Short-term effects of high dose estrogen on tibiae of growing male rats. Calcif. Tissue Int. 60 (1997) 37-42
7. Lees C.J., Register T.C., Turner C.H., Wang T., Stancill M., and Jerome C.P. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 9 (2002) 320-328
8. Burr D.B., and Turner C.H. Biomechanics of bone. In: Favus M. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2003), American Society for Bone and Mineral Research, Washington DC 58-64
9. Orwoll E. Toward an expanded understanding of the role of the periosteum in skeletal health. J. Bone Miner. Res. 18 (2003) 949-954
10. Beck T.J., Ruff C.B., Scott Jr. W.W., Plato C.C., Tobin J.D., and Quan C.A. Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif. Tissue Int. 50 (1992) 24-29
11. Delmas P.D. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30 (2002) 14-17
12. Marcus R., Wong M., Heath III H., and Stock J.L. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr. Rev. 23 (2002) 16-37
13. Delmas P.D. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?. Bone 27 (2000) 1-3
14. Russell R.G., Watts N.B., Ebetino F.H., and Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19 (2008) 733-759
15. Bikle D., Morey-Holton E., Doty S., Currier P., Tanner S., and Halloran B. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J. Bone Miner. Res. 9 (1994) 1777-1787
16. Iwata K., Li J., Follet H., Phipps R.J., and Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independent of resorption in rat femur and tibia. Bone 39 (2006) 1053-1058
17. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144 (2003) 5441-5449
18. Fuchs R.K., Phipps R.J., and Burr D.B. Recovery of trabecular and cortical bone turnover following discontinuation of risedronate and alendronate therapy in ovariectomized rats. J. Bone Miner. Res. 23 (2008) 1689-1697
19. Robling A.G., Hinant F.M., Burr D.B., and Turner C.H. Improved bone structure and strength after long-term mechanical loading is greatest if loading is separated into short bouts. J. Bone Miner. Res. 17 (2002) 1545-1554
20. Hsieh Y.F., Robling A.G., Ambrosius W.T., Burr D.B., and Turner C.H. Mechanical loading of diaphyseal bone in vivo: the strain threshold for an osteogenic response varies with location. J. Bone Miner. Res. 16 (2001) 2291-2297
21. Foldes J., Shih M.S., and Parfitt A.M. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J. Bone Miner. Res. 5 (1990) 1063-1067
22. Ebeling P.R., and Burr D.B. Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?. J. Bone Miner. Res. 23 (2008) 2-5
23. Bliziotes M., Sibonga J.D., Turner R.T., and Orwoll E. Periosteal remodeling at the femoral neck in nonhuman primates. J. Bone Miner. Res. 21 (2006) 1060-1067
24. Balena R., Shih M.S., and Parfitt A.M. Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J. Bone Miner. Res. 7 (1992) 1475-1482
25. Allen M.R., Hock J.M., and Burr D.B. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35 (2004) 1003-1012
26. Bare S., Recker S., Recker R., and Kimmel D. Influence of alendronate on periosteal and endocortical bone formation in the ilium of osteoporotic women. J. Bone Miner. Res. 20 (2005) SA414
27. Recker R., Coble T., Burshell A., Lombardi A., Rodan G., Kimmel D., et al. Effect of alendronate and estrogen replacement on periosteal bone formation in postmenopausal women. J. Bone Miner. Res. 16 (2001) 1176
28. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15 (2000) 613-620
29. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J. Bone Miner. Res. 19 (2004) 999-1005
30. Allen M.R., Follet H., Khurana M., and Burr D.B. Anti-remodeling agents influence osteoblast activity differently in modeling- and remodeling-associated bone formation. Calcif. Tissue Int. 79 (2006) 255-261
31. Yoshida Y., Moriya A., Kitamura K., Inazu M., Okimoto N., Okazaki Y., et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J. Bone Miner. Res. 13 (1998) 1011-1022
32. Lafage M.H., Balena R., Battle M.A., Shea M., Seedor J.G., Klein H., et al. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study. J. Clin. Invest. 95 (1995) 2127-2133
33. Vajda E.G., Hogue A., Griffiths K.N., Chang W.Y., Burnett K., Chen Y., et al. Combination treatment with a selective androgen receptor modulator (SARM) and a bisphosphonate has additive effects in osteopenic female rats. J. Bone Miner. Res. 24 (2008) 231-240
34. Iwamoto J., Seki A., Takeda T., Sato Y., Yamada H., and Yeh J.K. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Exp. Anim. 55 (2006) 357-367
35. Westerlind K.C., Wakley G.K., Evans G.L., and Turner R.T. Estrogen does not increase bone formation in growing rats. Endocrinology 133 (1993) 2924-2934
36. Baumann B.D., and Wronski T.J. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 16 (1995) 247-253
37. Yao W., Su M., Zhang Q., Tian X., Setterberg R.B., Blanton C., et al. Risedronate did not block the maximal anabolic effect of PTH in aged rats. Bone 41 (2007) 813-819
38. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., et al. The WNT co-receptor LRP5 is essential for skeletal mechanotransduction, but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem. 281 (2006) 63698-63711
39. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N. Y. Acad. Sci. 1117 (2007) 209-257
40. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2006) 617-627
41. Allen M.R., Iwata K., Phipps R., and Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39 (2006) 872-879
42. Allen M.R., and Burr D.B. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos. Int. 19 (2008) 95-99
43. Boonen S., Laan R.F., Barton I.P., and Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos. Int. 16 (2005) 1291-1298
44. Eriksen E.F., Melsen F., Sod E., Barton I., and Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
45. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100 (1997) 1475-1480
46. Stepan J.J., Burr D.B., Pavo I., Sipos A., Michalska D., Li J., et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41 (2007) 378-385
47. Recker R., Masarachia P., Santora A., Howard T., Chavassieux P., Arlot M., et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr. Med. Res. Opin. 21 (2005) 185-194
48. Recker R.R., Weinstein R.S., Chesnut III C.H., Schimmer R.C., Mahoney P., Hughes C., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos. Int. 15 (2004) 231-237
49. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., and Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191